Back to Trades
Total Value
$NaN
Filing Date
Mar 27, 2026
1 transactions
Trade Summary
On Mar 18, 2026, Hershman Ronnie, Director, reported $NaN of Nasus Pharma Ltd (NSRX) across 1 transactions. The filing covers company securities and reflects balanced net activity of $NaN. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Nasus Pharma Ltd
- Ticker Symbol
- NSRX
- CIK
- 0002029039
Insider Information
- Name
- Hershman Ronnie
- Role
- Director
Filing Details
- Filing Date
- Mar 27, 2026
- Transaction Date
- Mar 18, 2026
- Accession Number
- 0001493152-26-013384
- Form Type
- 3
Want live alerts when Hershman Ronnie trades again?
Download Insider Trades to track NSRX, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)Represents ordinary shares of the Issuer, no par value ("Ordinary Shares") directly held by Hershman Holdings, LLC. Dr. Ronnie Hershman, as the managing member of Hershman Holdings, LLC, may be deemed to beneficially own the Ordinary Shares owned directly by Hershman Holdings, LLC.
- (F2)Represents Ordinary Shares directly held by Phoenix Solutions Ltd. Dr. Ronnie Hershman, as a controlling shareholder of Phoenix Solutions Ltd., may be deemed to beneficially own the Ordinary Shares owned directly by Phoenix Solutions Ltd.
- (F3)The options to purchase 63,017 Ordinary Shares were granted on May 6, 2020, with 25% of the total grant vesting on May 6, 2021, and the remaining 75% vesting in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 63,017 options are vested and exercisable at an exercise price of $4.297 per share, expiring May 6, 2030.
- (F4)The warrants to purchase up to 17,970 Ordinary Shares (the "Warrants") were issued on February 13, 2026. The Warrants have an exercise price of $6.53 per share, were immediately exercisable, and will expire upon the earlier of two years from the date of issuance and 30 trading days following the Issuer's announcement of the top-line results of the Issuer's NS002 Pivotal Study. The Warrants are directly held by Hershman Holdings, LLC. Dr. Ronnie Hershman, as the managing member of Hershman Holdings, LLC, may be deemed to beneficially own the Warrants owned directly by Hershman Holdings, LLC.